Chengdu Easton Biopharmaceuticals Co., Ltd. Class ASSE: 688513

Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for YLSH003 for Injection and Completion of the 1st Subject Enrollment

· Issued by Chengdu Easton Biopharmaceuticals Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Initiation of Phase I/II Clinical Trial for YLSH003 for Injection and Completion of the 1st Subject Enrollment

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis